Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28567591 | 0.88 | ACHE (0.54) | ACHEKDM4CHSD17B10GAAL3MBTL1 | |
| SCHEMBL4233332 | 0.80 | ESRRG (0.60) | ACHEPLGPLAUPLA2G4A | |
| SCHEMBL21818907 | 0.79 | MEN1 (0.55) | ACHEKDM4CPLGPLAUPLA2G4A | |
| SCHEMBL31133372 | 0.79 | MEN1 (0.55) | ACHEKDM4CPLGPLAUPLA2G4A | |
| SCHEMBL1664063 | 0.79 | PLG (0.51) | PLGPLAUPLA2G4A | |
| SCHEMBL28312615 | 0.78 | KDM4E (0.50) | ACHEKDM4CHSD17B10GAAL3MBTL1 | |
| SCHEMBL4236255 | 0.78 | ESRRG (0.58) | PLGPLAUPLA2G4A | |
| SCHEMBL18539228 | 0.78 | PRKCI (0.46) | ACHEHSD17B10PLGPLAULMNA | |
| SCHEMBL4934703 | 0.77 | PLA2G4A (0.55) | PLGPLAUHCAR3PLA2G4A | |
| SCHEMBL17514249 | 0.76 | PLA2G4A (0.46) | PLGPLAUPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | ACHE 327/4885KDM4C 448/4885HSD17B10 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.